The incidence of amiodarone pulmonary toxicity (APT) varies from
The incidence and clinical predictors of amiodarone pulmonary toxicity
Although the
The incidence and clinical predictors of amiodarone pulmonary toxicity were
c) Discontinuation as soon as pulmonary toxicity is detected
The incidence of amiodarone pulmonary toxicity (APT) varies from about 4 to 17% of patients and is related to dosage, age of the patient, and pre-existing lung diseases
Recent reports have shown that PMX-DHP improves
This study was designed to evaluate the incidence and clinical risk factors of APT, and the utility of a pulmonary function test or serum KL-6 assay to predict pulmonary toxicity in
8,10 The incidence of amiodarone pulmonary toxicity (APT) varies from 0 to 61percent, 1-18 with an estimated mortality of 1 to 33 percent 1,7,8,14-16,18-20 A reasonable estimate of the current incidence would be that 5 to 7 percentof patients receiving The incidence of pulmonary toxicity from amiodarone is not precisely known; it is estimated to be 1 to 5 percent, depending on the dose of amiodarone [ 4-7 ]
The reported prevalence of pulmonary toxicity in patients receiving amiodarone is ~10% (range 2-18%) 8
Amiodarone is an effective antiarrhythmic that frequently is used during the perioperative period
This study was designed to evaluate the incidence and clinical risk factors of APT, and the utility of a pulmonary function test or serum KL-6 assay to predict pulmonary toxicity in
Compared to 200 mg/day of amiodarone, the pooled estimated incidence of overall side effects with a dose of 100 mg/day of amiodarone was 11% Fulmer JD
The clinical The incidence and clinical predictors of amiodarone pulmonary toxicity were examined in 573 patients treated with amiodarone for recurrent ventricular (456 patients) or supraventricular (117 patients) tachyarrhythmias
The incidence, risk factors, pathogenesis, and diagnosis of acute AIPT are speculative
Despite its clinical importance, there remain some
Patients with amiodarone-induced pulmonary toxicity usually present with dyspnea, non-productive cough, malaise, fever, and pleuritic chest pain ( 5 )
One study of 573 patients in a single-center study found the incidence of amiodarone pulmonary toxicity to be 5
The incidence and clinical predictors of amiodarone pulmonary toxicity were examined in 573 patients treated with amiodarone for recurrent ventricular (456 patients) or supraventricular (117 patients) tachyarrhythmias
We conducted a retrospective cohort study of
Amiodarone-induced pulmonary toxicity (APT) is a severe side effect that can lead to lung fibrosis or fatal respiratory failure
Perspective: Amiodarone has been used off-label for AF for >30 years and is a first-line rhythm-control strategy for patients with heart failure